SDS Separation Technology
Separates liquids from gases that are often very large, complex and expensive installations.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| investor | €0.0 | round | |
€2.0m | Series A | ||
| Total Funding | 000k | ||
SDS Separation Technology, founded in 2017 by Jonathan Jones and Christoph Brodesser, develops and provides novel solutions for downstream protein purification in the biopharmaceutical industry. The company originated from research conducted at the Jülich Research Centre and has since established its headquarters in Hamburg, Germany.
The core of its business is a proprietary chromatography process designed to purify therapeutic proteins, such as monoclonal antibodies, more efficiently and cost-effectively than traditional methods. Its technology is based on modifying the charge of proteins to enable their separation, offering a high-resolution, robust, and scalable alternative for the manufacturing of biologics. This process aims to reduce the number of steps required in downstream processing, thereby lowering production costs and increasing yield for biopharmaceutical manufacturers.
SDS Separation Technology targets pharmaceutical companies and contract development and manufacturing organizations (CDMOs) involved in the production of biotherapeutics. The business model revolves around licensing its patented technology and collaborating with partners to integrate its purification platform into their manufacturing workflows. The company has secured funding through various rounds, including a significant Series A financing, to advance its technology towards industrial-scale implementation.
Keywords: protein purification, chromatography, biopharmaceutical, downstream processing, monoclonal antibodies, biologics manufacturing, separation technology, therapeutic proteins, bioprocessing, industrial biotechnology